Topline results show that epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, demonstrated an improvement in PFS in patients receiving epcoritamab monotherapy (HR, 0.74; 95 ...
Surrounded by family and friends, Lane rang the bell, which symbolizes the end of cancer treatments, at Brenner Children’s ...
Results from the phase 3 EPCORE DLBCL-1 clinical trial show that patients with relapsed or refractory diffuse large B-cell ...
Despite the late-stage miss, analysts maintained confidence in the Epkinly program, with Truist Securities saying the result ...
Danish biotechnology company Genmab has announced top line results from the Phase III EPCORE DLBCL-1 trial, highlighting ...
Shares of Danish biotech Genmab fell as much as 5% on Friday, after is released disappointing top-line clinical results for ...
The drug is already approved in many countries for other lymphoma conditions and is marketed as Epkinly in the U.S. and ...
For patients who have chronic lymphocytic leukemia (CLL), experiencing Richter transformation with central nervous system ...
Nivolumab plus AVD significantly improves PFS compared to brentuximab vedotin plus AVD in advanced-stage classic Hodgkin lymphoma, with a 91% vs 82% 3-year PFS rate. The PFS benefit of nivolumab plus ...
Friday afternoon, the company and its partner Genmab shared word that the phase 3 Epcore DLBCL-1 trial missed on its primary ...
Asianet Newsable on MSN
Genmab reports mixed results from late-stage trial of lymphoma drug
Epcoritamab demonstrated an improvement in progression-free survival in certain patients with relapsed or refractory (R/R) ...
Topline results from a trial evaluating AbbVie and Genmab's epcoritamab to treat a type of lymphoma demonstrated an improvement in progression-free survival, the companies said. AbbVie and Genmab said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback